Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Cardiff Oncology reported strong first quarter 2026 results highlighted by successful End-of-Phase 2 FDA meeting, selection of onvansertib dose and chemotherapy regimen for Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC), and positive Phase 2 trial data showing improved efficacy with onvansertib combination therapy. The …